Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20+ Follicular Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT00006669
What this trial is testing

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Medstar Health Research Institute
Testing effectiveness (Phase 2)Study completedNCT00003397
What this trial is testing

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Maryland, Baltimore 25
Early research (Phase 1)Study completedNCT04578600
What this trial is testing

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic Leukemia+16 more
Joseph Tuscano 8
Early research (Phase 1)Study completedNCT04599634
What this trial is testing

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma+2 more
National Cancer Institute (NCI) 11
Large-scale testing (Phase 3)Study completedNCT02406092
What this trial is testing

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Who this might be right for
Non-Hodgkin Lymphoma
Hoffmann-La Roche 139
Testing effectiveness (Phase 2)Study completedNCT00073931
What this trial is testing

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Fred Hutchinson Cancer Center 25
Testing effectiveness (Phase 2)Temporarily pausedNCT03704714
What this trial is testing

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaCD20 Positive+5 more
Northwestern University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04663347
What this trial is testing

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Who this might be right for
Diffuse Large B-Cell LymphomaFollicular Lymphoma
Genmab 543
Testing effectiveness (Phase 2)Active Not RecruitingNCT04542824
What this trial is testing

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaPrimary Mediastinal Large B Cell Lymphoma+3 more
Genmab 78
Testing effectiveness (Phase 2)Ended earlyNCT00077961
What this trial is testing

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Who this might be right for
Non-Hodgkin's Lymphoma
Genzyme, a Sanofi Company 49
Early research (Phase 1)WithdrawnNCT00521261
What this trial is testing

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT02532257
What this trial is testing

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Who this might be right for
Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular Lymphoma+7 more
M.D. Anderson Cancer Center 48
Testing effectiveness (Phase 2)Looking for participantsNCT02393157
What this trial is testing

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Who this might be right for
Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma+3 more
New York Medical College 25
Early research (Phase 1)Ended earlyNCT00176475
What this trial is testing

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
University of Medicine and Dentistry of New Jersey 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT03888105
What this trial is testing

Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

Who this might be right for
B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals 515
Testing effectiveness (Phase 2)Ended earlyNCT01147393
What this trial is testing

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Who this might be right for
Follicular Lymphoma
Weill Medical College of Cornell University 4
Testing effectiveness (Phase 2)Ended earlyNCT00400764
What this trial is testing

Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas

Who this might be right for
Non-Hodgkin's Lymphoma
Genentech, Inc. 72
Early research (Phase 1)Active Not RecruitingNCT04007029
What this trial is testing

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more
Jonsson Comprehensive Cancer Center 24
Testing effectiveness (Phase 2)Study completedNCT00562978
What this trial is testing

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

Who this might be right for
Lymphoma
City of Hope Medical Center 54
Not applicableActive Not RecruitingNCT06070961
What this trial is testing

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

Who this might be right for
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS 56
Next Page